Clinical implications of dysregulated cytokine production

Journal of Molecular Medicine

Volumn 78, Issue 2, 2000, Pages 74-80

  Slifka, Mark K ^a   Whitton, J Lindsay ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

CD8+ T lymphocyte; Cytokine binding protein; Cytokine regulation; Immunopathology; Septic shock

Indexed keywords

CD8 ANTIGEN; CYTOKINE RECEPTOR; INTERLEUKIN 12; INTERLEUKIN 2; TUMOR NECROSIS FACTOR ALPHA;

CLONAL ANERGY; CYTOKINE PRODUCTION; HUMAN; HUMAN CELL; IMMUNOPATHOLOGY; IMMUNOREGULATION; RECEPTOR AFFINITY; REGULATORY MECHANISM; REVIEW; T LYMPHOCYTE ACTIVATION;

EID: 0034115161     PISSN: 09462716     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001090000086     Document Type: Review

References (83)

1. 1. Biron CA, Gazzinelli RT (1995) Effects of IL-12 on immune responses to microbial infections: a key mediator in regulating disease outcome. Curr Opin Immunol 7:485-496
2. 2. Guidotti LG, Chisari FV (1996) To kill or to cure: options in host defense against viral infection. Curr Opin Immunol 8: 478-483
3. 3. Tay CH, Welsh RM (1997) Distinct organ-dependent mechanisms for the control of murine cytomegalovirus infection by natural killer cells. J Virol 71:267-275
4. 4. Broek MF van den, Muller U, Huang S, Zinkernagel RM, Aguet M (1995) Immune defence in mice lacking type I and/or type II interferon receptors. Immunol Rev 148:5-18
5. 5. Arai KI, Lee F, Miyajima A, Miyatake S, Arai N, Yokota T (1990) Cytokines: coordinators of immune and inflammatory responses. Annu Rev Biochem 59:783-836
6. 6. Balkwill FR (1989) Tumour necrosis factor. Br Med Bull 45:389-400
7. 7. Tartour E, Mathiot C, Fridman WH (1992) Current status of interleukin-2 therapy in cancer. Biomed Pharmacother 46: 473-484
8. 8. Demetri GD, Spriggs DR, Sherman ML, Arthur KA, Imamura K, Kufe DW (1989) A phase I trial of recombinant human tumor necrosis factor and interferon-γ: effects of combination cytokine administration in vivo. J Clin Oncol 7:1545-1553
9. 9. Leonard JP, Sherman ML, Fisher GL, Buchanan LJ, Larsen G, Atkins MB, Sosman JA, Dutcher JP, Vogelzang NJ, Ryan JL (1997) Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-γ production. Blood 90:2541-2548
10. 10. Swaak AJ, Lienard D, Schraffordt KH, Lejeune FJ, Eggermont AM (1993) Effects of recombinant tumour necrosis factor (rTNF-α) in cancer. Observations on the acute phase protein reaction and immunoglobulin synthesis after high dose recombinant TNF-α administration in isolated limb perfusions in cancer patients. Eur J Clin Invest 23:812-818
11. 11. Schmidt-Wolf GD, Schmidt-Wolf IG (1995) Cytokines and gene therapy. Immunol Today 16:173-175
12. 12. Baumgartner JD, Glauser MP (1993) Immunotherapy of endotoxemia and septicemia. Immunobiology 187:464-477
13. 13. Bone RC (1995) Sepsis, sepsis syndrome, and the systemic inflammatory response syndrome (SIRS). Gulliver in Laputa. JAMA 273:155-156
14. 14. Cross AS (1994) Antiendotoxin antibodies: a dead end? Ann Intern Med 121:58-60
15. 15. Martin MA, Wenzel RP, Gorelick KJ (1991) Gram-negative bacterial sepsis in hospitals in the United States - natural history in the 1980s. Prog Clin Biol Res 367:111-119
16. 16. Danner RL, Elin RJ, Hosseini JM, Wesley RA, Reilly JM, Parillo JE (1991) Endotoxemia in human septic shock. Chest 99:169-175
17. 17. Glauser MP, Zanetti G, Baumgartner JD, Cohen J (1991) Septic shock: pathogenesis. Lancet 338:732-736
18. 18. Tracey KJ, Cerami A (1990) Metabolic responses to cachectin/TNF. A brief review. Ann NY Acad Sci 587:325-331
19. 19. Tracey KJ, Beutler B, Lowry SF, Merryweather J, Wolpe S, Milsark IW, Hariri RJ, Fahey TJ, Zentella A, Albert JD (1986) Shock and tissue injury induced by recombinant human cachectin. Science 234:470-474
20. 20. Tracey KJ, Fong Y, Hesse DG, Manogue KR, Lee AT, Kuo GC, Lowry SF, Cerami A (1987) Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 330:662-664
21. 21. Heaney ML, Golde DW (1998) Soluble receptors in human disease. J Leukoc Biol 64:135-146
22. 22. Fernandez-Botran R (1999) Soluble cytokine receptors: basic immunology and clinical applications. Crit Rev Clin Lab Sci 36:165-224
23. 23. Lotze MT, Custer MC, Sharrow SO, Rubin LA, Nelson DL, Rosenberg SA (1987) In vivo administration of purified human interleukin-2 to patients with cancer: development of interleukin-2 receptor positive cells and circulating soluble interleukin-2 receptors following interleukin-2 administration. Cancer Res 47:2188-2195
24. 24. Voss SD, Hank JA, Nobis CA, Fisch P, Sosman JA, Sondel PM (1989) Serum levels of the low-affinity interleukin-2 receptor molecule (TAC) during IL-2 therapy reflect systemic lymphoid mass activation. Cancer Immunol Immunother 29: 261-269
25. 25. Fernandez-Botran R (1991) Soluble cytokine receptors: their role in immunoregulation. FASEB J 5:2567-2574
26. 26. Arend WP (1995) Inhibiting the effects of cytokines in human diseases. Adv Intern Med 40:365-394
27. 27. Sato TA, Widmer MB, Finkelman FD, Madani H, Jacobs CA, Grabstein KH, Maliszewski CR (1993) Recombinant soluble murine IL-4 receptor can inhibit or enhance IgE responses in vivo. J Immunol 150:2717-2723
28. 28. Hale KK, Smith CG, Baker SL, Vanderslice RW, Squires CH, Gleason TM, Tucker KK, Kohno T, Russell DA (1995) Multifunctional regulation of the biological effects of TNF-α by the soluble type I and type II TNF receptors. Cytokine 7:26-38
29. 29. Aderka D, Engelmann H, Maor Y, Brakebusch C, Wallach D (1992) Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J Exp Med 175:323-329
30. 30. Heinrich PC, Behrmann I, Muller-Newen G, Schaper F, Graeve L (1998) Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem J 334:297-314
31. 31. Sanchez-Cuenca J, Martin JC, Pellicer A, Simon C (1999) Cytokine pleiotropy and redundancy-gp130 cytokines in human implantation. Immunol Today 20:57-59
32. 32. Muller-Newen G, Kohne C, Keul R, Hemmann U, Muller-Esterl W, Wijdenes J, Brakenhoff JP, Hart MH, Heinrich PC (1996) Purification and characterization of the soluble interleukin-6 receptor from human plasma and identification of an isoform generated through alternative splicing. Eur J Biochem 236:837-842
33. 33. Honda M, Yamamoto S, Cheng M, Yasukawa K, Suzuki H, Saito T, Osugi Y, Tokunaga T, Kishimoto T (1992) Human soluble IL-6 receptor: its detection and enhanced release by HIV infection. J Immunol 148:2175-2180
34. 34. Gaillard JP, Bataille R, Brailly H, Zuber C, Yasukawa K, Attal M, Maruo N, Taga T, Kishimoto T, Klein B (1993) Increased and highly stable levels of functional soluble interleukin-6 receptor in sera of patients with monoclonal gammopathy. Eur J Immunol 23:820-824
35. 35. Frey EA, Miller DS, Jahr TG, Sundan A, Bazil V, Espevik T, Finlay BB, Wright SD (1992) Soluble CD14 participates in the response of cells to lipopolysaccharide. J Exp Med 176:1665-1671
36. 36. Moreland LW, Baumgartner SW, Schiff MH, Tindall EA, Fleischmann RM, Weaver AL, Ettlinger RE, Cohen S, Koopman WJ, Mohler K, Widmer MB, Blosch CM (1997) Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 337:141-147
37. 37. Fisher CJ Jr, Agosti JM, Opal SM, Lowry SF, Balk RA, Sadoff JC, Abraham E, Schein RM, Benjamin E (1996) Treatment of septic shock with the tumor necrosis factor receptor: Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. N Engl J Med 334:1697-1702
38. 38. Turano A, Caruso A (1993) The role of human autoantibodies against γ-Interferon. J Antimicrob Chemother 32 [Suppl A]: 99-105
39. 39. Sylvester I, Suffredini AF, Boujoukos AJ, Martich GD, Danner RL, Yoshimura T, Leonard EJ (1993) Neutrophil attractant protein-1 and monocyte chemoattractant protein-1 in human serum. Effects of intravenous lipopolysaccharide on free attractants, specific IgG autoantibodies and immune complexes. J Immunol 151:3292-3298
40. 40. Trotter JL, Damico CA, Trotter AL, Collins KG, Cross AH (1995) Interleukin-2 binding proteins in sera from normal subjects and multiple sclerosis patients. Neurology 45:1971-1974
41. 41. Dicou E, Perrot S, Menkes CJ, Masson C, Nerriere V (1996) Nerve growth factor (NGF) autoantibodies and NGF in the synovial fluid: implications in spondylarthropathies. Autoimmunity 24:1-9
42. 42. Laricchia-Robbio L, Moscato S, Genua A, Liberati AM, Revoltella RP (1997) Naturally occurring and therapy-induced antibodies to human granulocyte colony-stimulating factor (G-CSF) in human serum. J Cell Physiol 173:219-226
43. 43. Svenson M, Bagge HM, Bendtzen K (1990) Distribution and characterization of autoantibodies to interleukin 1α in normal human sera. Scand J Immunol 32:695-701
44. 44. Ross C, Svenson M, Nielsen H, Lundsgaard C, Hansen MB, Bendtzen K (1997) Increased in vivo antibody activity against interferon-α, interleukin-1α, and interleukin-6 after high-dose Ig therapy. Blood 90:2376-2380
45. 45. Ross C, Svenson M, Hansen MB, Vejlsgaard GL, Bendtzen K (1995) High avidity IFN-neutralizing antibodies in pharmaceutically prepared human IgG. J Clin Invest 95:1974-1978
46. 46. Bendtzen K, Svenson M, Jonsson V, Hippe E (1990) Autoantibodies to cytokines-friends or foes? Immunol Today 11:167-169
47. 47. Special issue on anti-cytokine antibodies (1997) Biotherapy 10
48. 48. Bendtzen K, Hansen MB, Ross C, Svenson M (1998) High-avidity autoantibodies to cytokines. Immunol Today 19:209-211
49. 49. Dinarello CA (1992) Anti-cytokine strategies. Eur Cytokine Netw 3:7-17
50. 50. Henderson B, Blake S (1992) Therapeutic potential of cytokine manipulation. Trends Pharmacol Sci 13:145-152
51. 51. Klein B, Brailly H (1995) Cytokine-binding proteins: stimulating antagonists. Immunol Today 16:216-220
52. 52. Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen JS, Leeb B, Breedveld FC, Macfarlane JD, Bijl H (1994) Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis. Lancet 344:1105-1110
53. 53. Lu ZY, Brailly H, Rossi JF, Wijdenes J, Bataille R, Klein B (1993) Overall interleukin-6 production exceeds 7 mg/day in multiple myeloma complicated by sepsis. Cytokine 5:578-582
54. 54. Wendling D, Racadot E, Wijdenes J (1993) Treatment of severe rheumatoid arthritis by anti-interleukin 6 monoclonal antibody. J Rheumatol 20:259-262
55. 55. Beck JT, Hsu SM, Wijdenes J, Bataille R, Klein B, Vesole D, Hayden K, Jagannath S, Barlogie B (1994) Brief report: alleviation of systemic manifestations of Castleman's disease by monoclonal anti-interleukin-6 antibody. N Engl J Med 330: 602-605
56. 56. Emilie D, Wijdenes J, Gisselbrecht C, Jarrousse B, Billaud E, Blay JY, Gabarre J, Gaillard JP, Brochier J, Raphael M (1994) Administration of an anti-interleukin-6 monoclonal antibody to patients with acquired immunodeficiency syndrome and lymphoma: effect on lymphoma growth and on B clinical symptoms. Blood 84:2472-2479
57. 57. Castell J, Klapproth J, Gross V, Walter E, Andus T, Snyers L, Content J, Heinrich PC (1990) Fate of interleukin-6 in the rat. Involvement of skin in its catabolism. Eur J Biochem 189: 113-118
58. 58. Montero-Julian FA, Klein B, Gautherot E, Brailly H (1995) Pharmacokinetic study of anti-interleukin-6 (IL-6) therapy with monoclonal antibodies: enhancement of IL-6 clearance by cocktails of anti-IL-6 antibodies. Blood 85:917-924
59. 59. Jones AT, Ziltener HJ (1993) Enhancement of the biologic effects of interleukin-3 in vivo by anti-interleukin-3 antibodies. Blood 82:1133-1141
60. 60. Finkelman FD, Madden KB, Morris SC, Holmes JM, Boiani N, Katona IM, Maliszewski CR (1993) Anti-cytokine antibodies as carrier proteins. Prolongation of in vivo effects of exogenous cytokines by injection of cytokine-anti-cytokine antibody complexes. J Immunol 151:1235-1244
61. 61. Murali-Krishna K, Altman JD, Suresh M, Sourdive DJ, Zajac AJ, Miller JD, Slansky J, Ahmed R (1998) Counting antigen-specific CDS T cells: a reevaluation of bystander activation during viral infection. Immunity 8:177-187
62. + T cells in primary and secondary influenza pneumonia. Immunity 8:683-691
63. + T cells. Nature 401:76-79
64. 64. Kagi D, Ledermann B, Burki K, Seiler P, Odermatt B, Olsen KJ, Podack ER, Zinkernagel RM, Hengartner H (1994) Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice. Nature 369:31-37
65. 65. Walsh CM, Matloubian M, Liu CC, Ueda R, Kurahara CG, Christensen JL, Huang MT, Young JD, Ahmed R, Clark WR (1994) Immune function in mice lacking the perforin gene. Proc Natl Acad Sci USA 91:10854-10858
66. 66. Ramsay AJ, Ruby J, Ramshaw IA (1993) A case for cytokines as effector molecules in the resolution of virus infection. Immunol Today 14:155-157
67. 67. Gebhard JR, Perry CM, Harkins S, Lane T, Mena I, Asensio VC, Campbell IL, Whitton JL (1998) Coxsackievirus B3-induced myocarditis: perforin exacerbates disease, but plays no detectable role in virus clearance. Am J Pathol 153:417-428
68. 68. Selin LK, Varga SM, Wong IC, Welsh RM (1998) Protective heterologous antiviral immunity and enhanced immunopathogenesis mediated by memory T cell populations. J Exp Med 188:1705-1715
69. 69. Puglielli MT, Browning JL, Brewer AW, Schreiber RD, Shieh WJ, Altman JD, Oldstone MB, Zaki SR, Ahmed R (1999) Reversal of virus-induced systemic shock and respiratory failure by blockade of the lymphotoxin pathway. Nat Med 5: 1370-1374
70. + T cells can be distinguished by their cytokine profiles and phenotypic markers. J Immunol 164:208-216
71. 71. Ramsden L, Rider CC (1992) Selective and differential binding of interleukin (IL)-1α, IL-1β, IL-2 and IL-6 to glycosaminoglycans. Eur J Immunol 22:3027-3031
72. 72. Tanaka Y, Adams DH, Shaw S (1993) Proteoglycans on endothelial cells present adhesion-inducing cytokines to leukocytes. Immunol Today 14:111-115
73. 73. Roberts R, Gallagher J, Spooncer E, Allen TD, Bloomfield F, Dexter TM (1988) Heparan sulphate bound growth factors: a mechanism for stromal cell mediated haemopoiesis. Nature 332:376-378
74. 74. Gilat D, Cahalon L, Hershkoviz R, Lider O (1996) Interplay of T cells and cytokines in the context of enzymatically modified extracellular matrix. Immunol Today 17:16-20
75. 75. Cahalon L, Hershkoviz R, Gilat D, Miller A, Akiyama SK, Yamada KM, Lider O (1994) Functional interactions of fibronectin and TNFα: a paradigm of physiological linkage between cytokines and extracellular matrix moieties. Cell Adhes Commun 2:269-273
76. + T lymphocytes to the glycoprotein. J Immunol 152:1304-1313
77. + T cells via protein tyrosine phosphorylation. J Immunol 153:554-565
78. 78. Eigler A, Sinha B, Hartmann G, Endres S (1997) Taming TNF: strategies to restrain this proinflammatory cytokine. Immunol Today 18:487-492
79. 79. Tracey KJ, Cerami A (1994) Tumor necrosis factor: a pleiotropic cytokine and therapeutic target. Annu Rev Med 45: 491-503
80. 80. Jones AL, Selby P (1989) Tumour necrosis factor: clinical relevance. Cancer Surv 8:817-836
81. 81. Vassalli P (1992) The pathophysiology of tumor necrosis factors. Annu Rev Immunol 10:411-452
82. 82. West WH, Tauer KW, Yannelli JR, Marshall GD, Orr DW, Thurman GB, Oldham RK (1987) Constant-infusion recombinant interleukin-2 in adoptive inimunotherapy of advanced cancer. N Engl J Med 316:898-905
83. 83. Rosenberg SA, Lotze MT, Yang JC, Aebersold PM, Linehan WM, Seipp CA, White DE (1989) Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 210:474-484